
CLAIMS

1. A compound of formula (I):



(I)

wherein:

R1 represents a hydrogen atom or $(C_1\text{-}C_4)$-alkyl;

R2 represents $-(CH_2)_{n'}-B$ wherein:

n'=0, 1, 2, 3 or 4; and

B represents (i) $(C_3\text{-}C_5)$-cycloalkyl, (ii) $(C_1\text{-}C_4)$-alkyl optionally substituted with one or more fluorine atoms, or (iii) $(C_1\text{-}C_4)$-alkoxy;

Y, Z, V and **W** represent, independently of one another:

–CH-;

a carbon atom optionally substituted with R7, said R7 representing $(C_1\text{-}C_4)$-alkyl or a halogen atom;

a heteroatom selected from the group consisting of a nitrogen atom, a sulphur atom and an oxygen atom; or

no atom,

wherein the ring comprising V, W, Y and Z is a ring comprising 5 or 6 ring members, the dotted lines in said ring indicate that the resultant ring is an aromatic ring, and said ring comprises 0, 1 or 2 heteroatoms;

R3 and **R4** represent, independently of one another, groups that may be identical or different, R3 and R4 being selected from the group consisting of a hydrogen atom and linear $(C_1\text{-}C_4)$-alkyl; or **R3** and **R4** form, together with the carbon to which they are bound, $(C_3\text{-}C_5)$-cycloalkyl;

m is an integer equal to 1, 2, 3 or 4; and

R5 represents a hydrogen atom or $(C_1$-$C_4)$-alkyl, and **R6** represents -$(CH_2)_n$–**L** wherein:

n= 0, 1, 2 or 3, and

L is selected from the group consisting of:

an aryl comprising 6 carbon atoms;

a heteroaryl comprising between 5 and 6 ring members and comprising at least one heteroatom selected from the group consisting of nitrogen, oxygen and sulphur; and

a saturated heterocycle comprising 5, 6 or 7 ring members and comprising at least one heteroatom selected from the group consisting of nitrogen and oxygen, said heterocycle being optionally a lactam;

wherein said aryl, heteroaryl or heterocyclic group is optionally substituted with at least one substituent selected from the group consisting of (i) linear or branched $(C_1$-$C_4)$-alkyl, (ii) $(C_3$-$C_5)$-cycloalkyl, (iii) a halogen atom, (iv) aryl and (v) benzyl;

wherein when **L** is a heteroaryl or a heterocycle, said heteroaryl or heterocycle comprising at least one nitrogen atom, the heteroaryl or heterocycle can optionally be substituted with said substituent;

or **R5** and **R6** form, together with the nitrogen atom to which they are bound, a heterocyclic group, optionally substituted with at least

a heteroaryl, or

a $(C_1$-$C_3)$-alkyl, which is optionally substituted with a heterocycle comprising 5 or 6 atoms and comprising at least one heteroatom selected from the group consisting of nitrogen and oxygen, wherein when the $(C_1$-$C_3)$-alkyl is a heterocycle comprising at least one nitrogen atom, the heterocycle can optionally be substituted;

wherein said compound of formula (I) is in the form of a base or of an acid-addition salt thereof, or in the form of an enantiomer, diasteroisomer, or mixture thereof.

2. The compound according to claim 1, characterized in that **R6** represents -$(CH_2)_n$–**L** wherein:

n= 0, 1, 2 or 3, and

L is selected from the group consisting of:

a heteroaryl comprising 5 ring members and comprising (i) 2 heteroatoms selected, independently of one another, from the group consisting of nitrogen, oxygen and sulphur, or (ii) 3 heteroatoms selected, independently of one another, from the group consisting of nitrogen and sulphur,

a heteroaryl comprising 6 ring members and comprising 1 or 2 heteroatom(s),

a heterocycle comprising 5 ring members and comprising a heteroatom selected from the group consisting of nitrogen and oxygen, said heterocycle being optionally a lactam, and

a heterocycle comprising 6 ring members and comprising 2 heteroatoms selected from the group consisting of nitrogen and oxygen,

said heteroaryl or heterocycle being optionally substituted with at least one substituent selected from the group consisting of (i) linear or branched (C_1-C_4)-alkyl, (ii) (C_3-C_5)-cycloalkyl, (iii) a halogen atom, (iv) aryl and (v) benzyl,

wherein when **L** is a heteroaryl or a heterocycle comprising at least one nitrogen atom, the heteroaryl or heterocycle can optionally be substituted with said substituent.

3. The compound according to claim 1, wherein **L** is:

a heteroaryl comprising 6 ring members selected from the group consisting of pyridine, pyrazine, pyridazine, and pyrimidine;

an aryl such as phenyl;

a heteroaryl comprising 5 ring members selected from the group consisting of thiazole, imidazole, pyrazole, isoxazole and 1,3,4-thiadiazole;

a saturated heterocycle comprising 5 ring members selected from the group consisting of pyrrolidine, tetrahydrofuran and 2-oxo-pyrrolidine; or

a saturated heterocycle comprising 6 ring members selected from the group consisting of morpholine, piperazine, and piperidine;

wherein said aryl, heteroaryl or heterocyclic group is optionally substituted with at least one substituent selected from (i) linear or branched (C_1-C_4)-alkyl, (ii) (C_3-C_5)-cycloalkyl, and (iii) aryl,

and further wherein when **L** is a heteroaryl or a heterocycle comprising at least one nitrogen atom, the heteroaryl or a heterocycle can optionally be substituted with said substituent.

4. The compound according to claim 1, wherein **L** is selected from the group consisting of:

pyridine, optionally substituted with at least one linear or branched (C_1-C_4)-alkyl;

morpholine, optionally substituted with at least (i) (C_3-C_5)-cycloalkyl or (ii) linear or branched (C_1-C_4)-alkyl;

pyrrolidine, optionally substituted with at least (i) linear or branched (C_1-C_4)-alkyl, or (ii) benzyl;

thiazole, optionally substituted with at least (i) linear or branched (C_1-C_4)-alkyl, or (ii) a chlorine atom;

imidazole, optionally substituted with at least one linear or branched (C_1-C_4)-alkyl;

2-oxo-pyrrolidine;

1,3,4-thiadiazole, optionally substituted with at least (i) linear or branched (C_1-C_4)-alkyl, or (ii) a (C_3-C_5)-cycloalkyl;

isoxazole, optionally substituted with at least one linear or branched (C_1-C_4)-alkyl;

pyrazole, optionally substituted with at least one linear or branched (C_1-C_4)-alkyl;

pyrazine;

isothiazole, optionally substituted with at least one linear or branched (C_1-C_4)-alkyl;

phenyl; and

tetrahydrofuran,

wherein when **L** is a heteroaryl or a heterocycle comprising at least one nitrogen atom, the heteroaryl or heterocycle can optionally be substituted.

5. The compound according to claim 1, wherein **R5** represents a hydrogen atom or methyl.

6. The compound according to claim 1, wherein:

m is equal to 1 or 3, and/or

R3 and **R4** represent, independently of one another, groups that may be identical or different, R3 and R4 being selected from the group consisting of a hydrogen atom and methyl.

7. The compound according to claim 1, wherein **Y, Z, V** and **W** represent, independently of one another:

–CH-;

a carbon atom substituted with a group R7, said group R7 representing (C_1-C_4)-alkyl or a fluorine atom; or

a heteroatom selected from the group consisting of a nitrogen atom, a sulphur atom and an oxygen atom.

8. The compound according to claim 1, wherein **R1** represents a hydrogen atom or methyl.

9. The compound according to claim 1, wherein **R2** represents -$(CH_2)_n$–B wherein:

n'=0, 1 or 3; and/or

B represents (i) (C_3-C_5)-cycloalkyl, (ii) (C_1-C_4)-alkyl or (iii) a (C_1-C_4)-alkoxy.

10. The compound according to claim 1, wherein **R5** and **R6** form, together with the nitrogen atom to which they are bound, a heterocyclic group, optionally substituted with at least

a heteroaryl; or

(C_1-C_3)alkyl, which is optionally substituted with a heterocycle comprising 5 or 6 atoms and comprising at least one heteroatom selected from the group consisting of nitrogen and oxygen.

11. The compound according to claim 1, wherein the compound is in the form of a base or a salt of addition to an acid such as hydrochloric acid or trifluoroacetic acid.

12. The compound according to claim 1, wherein the compound is selected from the group consisting of:

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-2-yl-acetamide ;

2-{6-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-pyridin-3-yl}-N-pyridin-2-yl-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(4-cyclopropyl-morpholin-3-ylmethyl)-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(4-isopropyl-morpholin-3-ylmethyl)-acetamide ;

2-Amino-1-ethyl-3-(1H-imidazol-2-yl)-7-{4-[2-oxo-2-((S)-2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-ethyl]-phenyl}-1H-[1,8]naphthyridin-4-one ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-

phenyl}-N-(2-pyridin-4-yl-ethyl)-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-methyl-N-(2-pyridin-4-yl-ethyl)-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(5-methyl-thiazol-2-yl)-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-3-methyl-phenyl}-N-(1-ethyl-pyrrolidin-2-ylmethyl)-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(6-methyl-pyridin-3-yl)-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(1,3-dimethyl-1H-pyrazol-4-ylmethyl)-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-thiazol-2-ylmethyl-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(5-oxo-pyrrolidin-2-ylmethyl)-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(5-methyl-[1,3,4]thiadiazol-2-yl)-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-[1,3,4]thiadiazol-2-yl-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(3-methyl-isoxazol-5-yl)-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-[2-(1-methyl-pyrrolidin-2-yl)-ethyl]-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(4-methyl-thiazol-2-yl)-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(5-cyclopropyl-[1,3,4]thiadiazol-2-yl)-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(2-pyridin-3-yl-ethyl)-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(2,5-dimethyl-2H-pyrazol-3-ylmethyl)-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-

phenyl}-N-(1-methyl-1H-imidazol-4-ylmethyl)-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyrazin-2-yl-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(2-pyridin-2-yl-ethyl)-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(5-chloro-thiazol-2-yl)-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(3,4-dimethyl-isoxazol-5-yl)-acetamide;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(2-methyl-pyridin-4-yl)-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyrazin-2-ylmethyl-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(5-ethyl-[1,3,4]thiadiazol-2-yl)-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(tetrahydro-furan-2-ylmethyl)-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(3-methyl-pyridin-2-yl)-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(4-methyl-pyridin-2-yl)-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(4,6-dimethyl-pyridin-2-yl)-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(6-methyl-pyridin-2-yl)-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-3-ylmethyl-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(2-ethyl-2H-pyrazol-3-yl)-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(3-methyl-isothiazol-5-yl)-acetamide ;

2-Amino-1-ethyl-3-(1H-imidazol-2-yl)-7-{4-[2-oxo-2-(2-pyridin-3-yl-pyrrolidin-1-yl)-ethyl]-phenyl}-1H-[1,8]naphthyridin-4-one ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-

phenyl}-N-(1-benzyl-pyrrolidin-3-yl)-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-[(S)-1-(tetrahydro-furan-2-yl)methyl]-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(4-methyl-pyridin-3-yl)-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(4-ethyl-pyridin-2-yl)-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-ethyl-N-pyridin-4-ylmethyl-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(6-ethyl-pyridin-2-yl)-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-benzyl-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-propionamide ;

4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-N-pyridin-4-ylmethyl-benzamide ;

4-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-butyramide ;

2-{4-[7-Amino-8-ethyl-6-(4-methyl-1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-acetamide ;

2-{4-[7-Amino-8-cyclopropylmethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-acetamide ;

2-{4-[7-Amino-8-cyclopentyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-acetamide ;


2-{5-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-pyridin-2-yl}-N-pyridin-4-ylmethyl-acetamide ;

2-{4-[7-Amino-6-(1H-imidazol-2-yl)-8-(3-methoxy-propyl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-acetamide ;

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(3-phenyl-propyl)-acetamide ; and


2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-2-fluoro-phenyl}-N-(1-ethyl-pyrrolidin-2-ylmethyl)-acetamide.

13. A process for preparing the compound according to claim 1, comprising the step of reacting a compound of formula (VII):




(VII)

wherein Pg represents a protecting group and X represents a halogen atom,
with a boronic acid or a boronic ester of pinacol of formula (IXa):




(IXa)

wherein G represents -NR5R6 or G represents -OEt;
to obtain respectively a compound of formula (X):



(X)


wherein G represents a -NR5R6 and Pg is a protecting group;
or a compound of formula (XI):



(XI)


wherein G represents –OEt and Pg is a protecting group;
and wherein m, R1, R2, R3, R4, R5, R6, V, W, Y and Z are as defined in Claim 1.

14. A process for preparing the compound according to claim 1, comprising the step of reacting a compound of formula (VIII):




(VIII)

wherein Pg represents a protecting group,
with an aryl or heteroaryl halide of formula (IXb):




(IXb)

wherein G represents -OEt or -NR5R6 and X represents a halogen atom;
to obtain a compound of formula (X):



(X)


wherein G represents -NR5R6 and Pg is protecting group,
or a compound of formula (XI):



(XI)

wherein G represents -OEt,
and wherein m, R1, R2, R3, R4, R5, R6, V, W, Y and Z are as defined in Claim 1.

15. The process according to claim 13, comprising saponifying and then peptide coupling with the amine HNR5R6 a compound of formula (XI) wherein G represents -OEt, to obtain a compound of formula (XIII):




(XIII)

wherein Pg represents a protecting group and wherein m, R1, R2, R3, R4, R5, R6, V, W, Y and Z are as defined in Claim 1.

16. A pharmaceutical composition comprising the compound according to claim 1 and at least one pharmaceutically acceptable excipient.

17. The process according to claim 14, comprising saponifying and then peptide coupling with the amine HNR5R6 a compound of formula (XI) wherein G represents -OEt, to obtain a compound of formula (XIII):



wherein Pg represents a protecting group and wherein m, R1, R2, R3, R4, R5, R6, V, W, Y and Z are as defined in Claim 1.

18. The compound according to claim 1, wherein **Y, Z, V** and **W** represent, independently of one another:

–CH-;

a carbon atom substituted with a group R7, said group R7 representing (C_1-C_4)-alkyl or a fluorine atom; or

a nitrogen atom.

19. The compound according to claim 1, wherein **R5** and **R6** form, together with the nitrogen atom to which they are bound, a heterocyclic group, optionally substituted with at least

a pyridine; or

(C_1-C_3)alkyl, which is optionally substituted with a heterocycle comprising 5 or 6 atoms and comprising at least one heteroatom selected from the group consisting of nitrogen and oxygen.


20. The compound according to claim 1, wherein **R5** and **R6** form, together with the nitrogen atom to which they are bound, a heterocyclic group, optionally substituted with at least

a heteroaryl; or

a C1alkyl group substituted with a heterocycle comprising 5 atoms including a nitrogen atom.

CLAIMS

1. Compound corresponding to formula (I):



(I)

in which,

R1 represents a hydrogen atom or a $(C_1$-$C_4)$alkyl group;

R2 represents a group $-(CH_2)_n$–B where:

- n'=0, 1, 2, 3 or 4; and
- B represents (i) a $(C_3$-$C_5)$cycloalkyl group or a $(C_1$-$C_4)$alkyl group, said group being optionally substituted with one or more fluorine atoms, or (ii) a $(C_1$-$C_4)$alkoxy group;

Y, Z, V and **W** represent, independently of one another:

- a –CH- group,
- a carbon atom optionally substituted with a group R7, said group R7 representing a $(C_1$-$C_4)$alkyl group or a halogen atom,
- a heteroatom such as a nitrogen atom, a sulphur atom or an oxygen atom, or
- no atom,

it being understood that the ring in which V, W, Y and Z are comprised is a ring comprising 5 or 6 ring members, it being understood that the dotted lines in said ring indicate that the resultant ring is an aromatic ring and it being understood that said ring comprises 0, 1 or 2 heteroatoms;

R3 and **R4** represent, independently of one another, groups that may be identical or different, R3 and R4 being selected from:

- a hydrogen atom; and

- a linear (C_1-C_4)alkyl group;

or **R3** and **R4** form, together with the carbon to which they are bound, a (C_3-C_5)cycloalkyl group;

m is an integer equal to 1, 2, 3 or 4;

R5 represents a hydrogen atom or a (C_1-C_4)alkyl group;

R6 represents a group -$(CH_2)_n$–**L** in which:

- n= 0, 1, 2 or 3, and
- **L** is a group selected from the following groups:
  - an aryl comprising 6 carbon atoms;
  - a heteroaryl comprising between 5 and 6 ring members and comprising at least one heteroatom selected from nitrogen, oxygen and sulphur;
  - a saturated heterocycle comprising 5, 6 or 7 ring members and comprising at least one heteroatom selected from nitrogen and oxygen, said heterocycle being optionally a lactam;

  said aryl, heteroaryl or heterocyclic group being optionally substituted with at least one substituent selected from (i) linear or branched (C_1-C_4)alkyl groups, (ii) (C_3-C_5)cycloalkyl groups, (iii) halogen atoms, (iv) aryls and (v) benzyl;

it being understood that when **L** is a heteroaryl or a heterocycle, said heteroaryl or heterocycle comprising at least one nitrogen atom, the latter can optionally be substituted with said substituent;

or **R5** and **R6** form, together with the nitrogen atom to which they are bound, a heterocyclic group, optionally substituted with at least

- a heteroaryl, or
- a (C_1-C_3)alkyl group, which can itself be substituted with a heterocycle comprising 5 or 6 atoms and comprising at least one heteroatom selected from nitrogen and oxygen, it being understood that when it is a heterocycle comprising at least one nitrogen atom, the latter can optionally be substituted;

said compound of formula (I), its enantiomers and diastereoisomers, including mixtures thereof, being in the form of a base or a salt of acid addition and/or in the form of solvate.

2. Compound according to the preceding claim, characterized in that **R6** represents a group -$(CH_2)_n$–**L** in which:

- n= 0, 1, 2 or 3, and
- **L** is a group selected from the following groups:
  - a heteroaryl comprising 5 ring members and comprising (i) 2 heteroatoms selected, independently of one another, from nitrogen, oxygen and sulphur, or (ii) 3 heteroatoms selected, independently of one another, from nitrogen and sulphur,
  - a heteroaryl comprising 6 ring members and comprising 1 or 2 heteroatom(s),
  - a heterocycle comprising 5 ring members and comprising a heteroatom selected from nitrogen and oxygen, said heterocycle being optionally a lactam, and
  - a heterocycle comprising 6 ring members and comprising 2 heteroatoms selected from nitrogen and oxygen,

said heteroaryl group or heterocycle being optionally substituted with at least one substituent selected from (i) linear or branched (C_1-C_4)alkyl groups, (ii) (C_3-C_5)cycloalkyl groups, (iii) halogen atoms, (iv) aryls and (v) benzyl,

it being understood that when **L** is a heteroaryl or a heterocycle, said heteroaryl or heterocycle comprising at least one nitrogen atom, the latter can optionally be substituted with said substituent.

3. Compound according to any one of the preceding claims, characterized in that **L** is:

- a heteroaryl comprising 6 ring members selected from pyridine, pyrazine, pyridazine, pyrimidine;
- an aryl such as phenyl, or
- a heteroaryl comprising 5 ring members selected from thiazole, imidazole, pyrazole, isoxazole and 1,3,4-thiadiazole, or

- a saturated heterocycle comprising 5 ring members selected from pyrrolidine, tetrahydrofuran and 2-oxo-pyrrolidine or
- a saturated heterocycle comprising 6 ring members selected from morpholine, piperazine, piperidine,

said aryl, heteroaryl or heterocyclic group being optionally substituted with at least one substituent selected from (i) linear or branched (C_1-C_4)alkyl groups, (ii) (C_3-C_5)cycloalkyl groups and (iii) aryls,

it being understood that when **L** is a heteroaryl or a heterocycle, said heteroaryl or heterocycle comprising at least one nitrogen atom, the latter can optionally be substituted with said substituent.

4. Compound according to any one of the preceding claims, characterized in that **L** is selected from:

- pyridine, optionally substituted with at least one linear or branched (C_1-C_4)alkyl group,
- morpholine, optionally substituted with at least (i) a (C_3-C_5)cycloalkyl group or (ii) a linear or branched (C_1-C_4)alkyl group,
- a pyrrolidine, optionally substituted with at least (i) a linear or branched (C_1-C_4)alkyl group, or (ii) a benzyl,
- a thiazole, optionally substituted with at least (i) a linear or branched (C_1-C_4)alkyl group, or (ii) a chlorine atom,
- an imidazole, optionally substituted with at least one linear or branched (C_1-C_4)alkyl group,
- a 2-oxo-pyrrolidine,
- a 1,3,4-thiadiazole, optionally substituted with at least (i) a linear or branched (C_1-C_4)alkyl group, or (ii) a (C_3-C_5)cycloalkyl group,
- an isoxazole, optionally substituted with at least one linear or branched (C_1-C_4)alkyl group,
- a pyrazole, optionally substituted with at least one linear or branched (C_1-C_4)alkyl group,
- a pyrazine,
- an isothiazole, optionally substituted with at least one linear or branched (C_1-C_4)alkyl group,

- a phenyl,
- a tetrahydrofuran,

it being understood that when **L** is a heteroaryl or a heterocycle, said heteroaryl or heterocycle comprising at least one nitrogen atom, the latter can optionally be substituted.

5. Compound according to any one of the preceding claims, characterized in that **R5** represents a hydrogen atom or a methyl.

6. Compound according to any one of the preceding claims, characterized in that:

- m is equal to 1 or 3, and/or
- **R3** and **R4** represent, independently of one another, groups that may be identical or different, R3 and R4 being selected from:
  - a hydrogen atom, and
  - a methyl.

7. Compound according to any one of the preceding claims, characterized in that **Y, Z, V** and **W** represent, independently of one another:

- a group –CH–;
- a carbon atom substituted with a group R7, said group R7 representing a (C_1-C_4)alkyl group or a fluorine atom; or
- a heteroatom such as a nitrogen atom, a sulphur atom or an oxygen atom, advantageously a nitrogen atom.

8. Compound according to any one of the preceding claims, characterized in that **R1** represents a hydrogen atom or a methyl.

9. Compound according to any one of the preceding claims, characterized in that **R2** represents a group -(CH_2)$_n$–B where:

- n'=0, 1 or 3; and/or
- B represents (i) a (C_3-C_5)cycloalkyl group, (ii) a (C_1-C_4)alkyl group or (iii) a (C_1-C_4)alkoxy group.

10. Compound according to any one of Claims 1 and 6 to 9, characterized in that **R5** and **R6** form, together with the nitrogen atom to which they are bound, a heterocyclic group, optionally substituted with at least

- a heteroaryl, advantageously a pyridine; or
- a (C_1-C_3)alkyl group, which can itself be substituted with a heterocycle comprising 5 or 6 atoms and comprising at least one heteroatom selected from nitrogen and oxygen, advantageously it is a C1alkyl group, itself substituted with a heterocycle comprising 5 atoms including a nitrogen atom.

11. Compound according to any one of the preceding claims, characterized in that it is in the form of a base or a salt of addition to an acid such as hydrochloric acid or trifluoroacetic acid.

12. Compound according to any one of the preceding claims, characterized in that it is:

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-2-yl-acetamide (compound 1);

2-{6-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-pyridin-3-yl}-N-pyridin-2-yl-acetamide (compound 2);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(4-cyclopropyl-morpholin-3-ylmethyl)-acetamide (compound 3);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(4-isopropyl-morpholin-3-ylmethyl)-acetamide (compound 4);

2-Amino-1-ethyl-3-(1H-imidazol-2-yl)-7-{4-[2-oxo-2-((S)-2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-ethyl]-phenyl}-1H-[1,8]naphthyridin-4-one (compound 5);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(2-pyridin-4-yl-ethyl)-acetamide (compound 6);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-methyl-N-(2-pyridin-4-yl-ethyl)-acetamide (compound 7);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(5-methyl-thiazol-2-yl)-acetamide (compound 8);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-3-methyl-phenyl}-N-(1-ethyl-pyrrolidin-2-ylmethyl)-acetamide (compound 9);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(6-methyl-pyridin-3-yl)-acetamide (compound 10);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(1,3-dimethyl-1H-pyrazol-4-ylmethyl)-acetamide (compound 11);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-thiazol-2-ylmethyl-acetamide (compound 12);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(5-oxo-pyrrolidin-2-ylmethyl)-acetamide (compound 13);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(5-methyl-[1,3,4]thiadiazol-2-yl)-acetamide (compound 14);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-[1,3,4]thiadiazol-2-yl-acetamide (compound 15);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(3-methyl-isoxazol-5-yl)-acetamide (compound 16);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-[2-(1-methyl-pyrrolidin-2-yl)-ethyl]-acetamide (compound 17);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(4-methyl-thiazol-2-yl)-acetamide (compound 18);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-acetamide (compound 19);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(5-cyclopropyl-[1,3,4]thiadiazol-2-yl)-acetamide (compound 20);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(2-pyridin-3-yl-ethyl)-acetamide (compound 21);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(2,5-dimethyl-2H-pyrazol-3-ylmethyl)-acetamide (compound 22);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(1-methyl-1H-imidazol-4-ylmethyl)-acetamide (compound 23);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyrazin-2-yl-acetamide (compound 24);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(2-pyridin-2-yl-ethyl)-acetamide (compound 25);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(5-chloro-thiazol-2-yl)-acetamide (compound 26);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(3,4-dimethyl-isoxazol-5-yl)-acetamide (compound 27);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(2-methyl-pyridin-4-yl)-acetamide (compound 28);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyrazin-2-ylmethyl-acetamide (compound 29);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(5-ethyl-[1,3,4]thiadiazol-2-yl)-acetamide (compound 30);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(tetrahydro-furan-2-ylmethyl)-acetamide (compound 31);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(3-methyl-pyridin-2-yl)-acetamide (compound 32);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(4-methyl-pyridin-2-yl)-acetamide (compound 33);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(4,6-dimethyl-pyridin-2-yl)-acetamide (compound 34);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(6-methyl-pyridin-2-yl)-acetamide (compound 35);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-3-ylmethyl-acetamide (compound 36);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(2-ethyl-2H-pyrazol-3-yl)-acetamide (compound 37);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(3-methyl-isothiazol-5-yl)-acetamide (compound 38);

2-Amino-1-ethyl-3-(1H-imidazol-2-yl)-7-{4-[2-oxo-2-(2-pyridin-3-yl-pyrrolidin-1-yl)-ethyl]-phenyl}-1H-[1,8]naphthyridin-4-one (compound 39);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(1-benzyl-pyrrolidin-3-yl)-acetamide (compound 40);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-[(S)-1-(tetrahydro-furan-2-yl)methyl]-acetamide (compound 41);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(4-methyl-pyridin-3-yl)-acetamide (compound 42);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(4-ethyl-pyridin-2-yl)-acetamide (compound 43);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-ethyl-N-pyridin-4-ylmethyl-acetamide (compound 44);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(6-ethyl-pyridin-2-yl)-acetamide (compound 45);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-benzyl-acetamide (compound 46);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-propionamide (compound 47);

4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-N-pyridin-4-ylmethyl-benzamide (compound 48);

4-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-butyramide (compound 49);

2-{4-[7-Amino-8-ethyl-6-(4-methyl-1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-acetamide (compound 50);

2-{4-[7-Amino-8-cyclopropylmethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-acetamide (compound 51);

2-{4-[7-Amino-8-cyclopentyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-acetamide (compound 52);

2-{5-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-pyridin-2-yl}-N-pyridin-4-ylmethyl-acetamide (compound 53);

2-{4-[7-Amino-6-(1H-imidazol-2-yl)-8-(3-methoxy-propyl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-acetamide (compound 54);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(3-phenyl-propyl)-acetamide (compound 55);


2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-2-fluoro-phenyl}-N-(1-ethyl-pyrrolidin-2-ylmethyl)-acetamide (compound 56).

13. Process for preparing a compound of formula (I) according to any one of Claims 1 to 12, characterized in that (i) a compound of the following formula (VII):



in which Pg represents a protecting group and X represents a halogen atom,


is reacted according to a Suzuki coupling reaction with (ii) a boronic acid or a boronic ester of pinacol of formula (IXa):



(IXa)


in which G represents a group -NR5R6 or G represents a group -OEt;

in order to obtain respectively (iii) a compound of the following formula (X):




in which G represents a group -NR5R6 and Pg is as defined previously;

or (iv) a compound of the following formula (XI):




in which G represents a group –OEt and Pg is as defined previously;
it being understood that m, R1, R2, R3, R4, R5, R6, V, W, Y and Z are as defined in Claim 1.

14. Process for preparing a compound of formula (I) according to any one of Claims 1 to 12, characterized in that (i) a compound of formula (VIII):




in which Pg represents a protecting group;
is reacted according to a Stille coupling reaction with (ii) an aryl or heteroaryl halide of the following formula (IXb):




(IXb)

in which G represents a group -OEt or G represents a group -NR5R6 and X represents a halogen atom;
in order to obtain (iii) a compound of the following formula (X):




for which G represents a group -NR5R6 and Pg is as defined previously;
or (iv) a compound (XI) of the following formula:



for which G represents a group -OEt,

it being understood that m, R1, R2, R3, R4, R5, R6, V, W, Y and Z are as defined in Claim 1.

15. Process for preparing a compound of formula (I) according to one of Claims 13 or 14, characterized in that the compound (XI) for which G represents a group -OEt then undergoes a stage of saponification and then a stage of peptide coupling with the amine HNR5R6, giving the compound (XIII) of the following formula:



(XIII)

it being understood that Pg represents a protecting group and that m, R1, R2, R3, R4, R5, R6, V, W, Y and Z are as defined in Claim 1.

16. Medicinal product, characterized in that it comprises a compound of formula (I) according to any one of Claims 1 to 12, or a salt of addition of this compound to a pharmaceutically acceptable acid, or a solvate of the compound of formula (I).

17. Pharmaceutical composition, characterized in that it comprises a compound of formula (I) according to any one of Claims 1 to 12, or a pharmaceutically acceptable salt, a solvate of this compound, as well as at least one pharmaceutically acceptable excipient.

18. Use of a compound of formula (I) according to any one of Claims 1 to 12 for

preparing a medicinal product intended for treating diseases linked to the activity of protein kinases, said compound of formula (I) inhibiting the tyrosine kinase activity of PDGF-R, in particular PDGF-R beta, in Baf3 tel/PDGF cells and/or inhibiting the tyrosine kinase activity of Flt-3 in MV4-11 cells.

19. Use of a compound of formula (I) according to any one of Claims 1 to 12 for preparing a medicinal product intended for the treatment of proliferative diseases such as cancers with liquid tumours, chronic or acute leukaemias, lymphocytic lymphomas, Hodgkin's disease, myeloproliferative syndromes and myelodysplastic syndromes.

20. Use of a compound of formula (I) according to any one of Claims 1 to 12 for preparing a medicinal product intended for the treatment of proliferative diseases such as cancers with solid tumours comprising lung cancers (NSCLC), cancers of bone, pancreas, skin, Kaposi syndrome, intraocular melanomas, cancers associated with sexual organs comprising cancer of the breast, uterus, cervix, ovary, endometrium, vagina, vulva, urethra, penis, prostate, carcinomas of the fallopian tubes, cancers of the gastrointestinal stromal tumour type (abbreviation: GIST) comprising cancers of the anal region, rectum, small intestine, colon, stomach, oesophagus, cancers of endocrine glands, thyroid, parathyroid or adrenal glands, soft tissue sarcomas, Ewing sarcomas, osteosarcomas, dermatofibrosarcomas and other fibrosarcomas, cancers of the bladder or kidney, neoplasms of the central nervous system, tumours of the vertebral column and desmoids, gliomas of the brainstem and glioblastomas, pituitary adenomas and metastases thereof.

21. Use of a compound of formula (I) according to any one of Claims 1 to 12 for preparing a medicinal product intended for the treatment of non-malignant proliferative diseases such as restenosis, atherosclerosis, thrombosis, heart failure, cardiac hypertrophy, pulmonary arterial hypertension, fibrosis, diabetic nephropathy, glomerulonephritis, chronic pyelonephritis, haemangiomas, auto-immune diseases such as psoriasis, sclerodermatitis, immunosuppression, pathologies of the eye such as post-operative fibrosis and age-related macular degeneration.

22. Compound of formula (I) according to any one of Claims 1 to 12 for preparing a medicinal product intended for the treatment of proliferative diseases such as cancers

with liquid tumours, chronic or acute leukaemias, lymphocytic lymphomas, Hodgkin's disease, myeloproliferative syndromes and myelodysplastic syndromes.

23. Compound of formula (I) according to any one of Claims 1 to 12 for preparing a medicinal product intended for the treatment of proliferative diseases such as cancers with solid tumours comprising lung cancers (NSCLC), cancers of bone, pancreas, skin, Kaposi syndrome, intraocular melanomas, cancers associated with sexual organs comprising cancer of the breast, uterus, cervix, ovary, endometrium, vagina, vulva, urethra, penis, prostate, carcinomas of the fallopian tubes, cancers of the gastrointestinal stromal tumour type (abbreviation: GIST) comprising cancers of the anal region, rectum, small intestine, colon, stomach, oesophagus, cancers of endocrine glands, thyroid, parathyroid or adrenal glands, soft tissue sarcomas, Ewing sarcomas, osteosarcomas, dermatofibrosarcomas and other fibrosarcomas, cancers of the bladder or kidney, neoplasms of the central nervous system, tumours of the vertebral column and desmoids, gliomas of the brainstem and glioblastomas, pituitary adenomas and metastases thereof.

24. Compound of formula (I) according to any one of Claims 1 to 12 for preparing a medicinal product intended for the treatment of non-malignant proliferative diseases such as restenosis, atherosclerosis, thrombosis, heart failure, cardiac hypertrophy, pulmonary arterial hypertension, fibrosis, diabetic nephropathy, glomerulonephritis, chronic pyelonephritis, haemangiomas, auto-immune diseases such as psoriasis, sclerodermatitis, immunosuppression, pathologies associated with the eye such as post-operative fibrosis or age-related macular degeneration.

25. Combination of at least one compound of formula (I) according to any one of Claims 1 to 12 with at least one chemotherapy agent.